Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2025
Anal neoplasm: Streamline follow-up of low-grade dysplasia.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Carlo Aurore, Siproudhis Laurent, Landemaine Amandine, Gouriou Claire, Grolhier Claire, Lièvre Astrid, Henno Sébastien, Brochard Charlène
Аннотация
BACKGROUND: Screening strategies for anal cancer are based on repeated assessments in targeted populations. Low-grade lesions are frequently diagnosed, but the progression to invasive cancer is not the rule. The aim of the present study was to identify risk levels in these patients to refine screening strategies.
METHODS: The data of consecutive patients referred for screening of anal intraepithelial lesions were collected prospectively. Patients with low-grade intraepithelial lesions (LSILs) at referral and at least two clinical evaluations, including cytology and virology, were included. HPV DNA screening, high-grade lesion (HSIL) and invasive cancer incidence data were extracted.
RESULTS: From April 2010 to December 2020, 194 patients with LSILs were included, with a median follow-up of 48 months. The cumulative probabilities of HSILs were 13.7% [9.5-19.4] at 1 year and 44.4% [35.9-53.3] at 5 years. Past history of HIV, HPV lesions, HPV subtypes (except HPV16), tobacco consumption and body mass index were not significantly related to HSILs. HPV16 status and age older than 44 years at baseline were associated with a greater risk of HSIL.
CONCLUSIONS: Patients with LSIL have a low risk of HSILs, except those with HPV16 subtype at baseline. After a first-year a reasonable recommendation may be a 4-year interval between two screening visits.
METHODS: The data of consecutive patients referred for screening of anal intraepithelial lesions were collected prospectively. Patients with low-grade intraepithelial lesions (LSILs) at referral and at least two clinical evaluations, including cytology and virology, were included. HPV DNA screening, high-grade lesion (HSIL) and invasive cancer incidence data were extracted.
RESULTS: From April 2010 to December 2020, 194 patients with LSILs were included, with a median follow-up of 48 months. The cumulative probabilities of HSILs were 13.7% [9.5-19.4] at 1 year and 44.4% [35.9-53.3] at 5 years. Past history of HIV, HPV lesions, HPV subtypes (except HPV16), tobacco consumption and body mass index were not significantly related to HSILs. HPV16 status and age older than 44 years at baseline were associated with a greater risk of HSIL.
CONCLUSIONS: Patients with LSIL have a low risk of HSILs, except those with HPV16 subtype at baseline. After a first-year a reasonable recommendation may be a 4-year interval between two screening visits.